Skip to content

Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children

Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03354741
Acronym
NAUVOLA
Enrollment
30
Registered
2017-11-28
Start date
2019-05-23
Completion date
2023-09-23
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced Nausea and Vomiting, Children, Malignant Tumor

Brief summary

Poor control of chemotherapy-induced nausea and vomiting has a major clinical and psychological impact in patients treated with chemotherapy. Metabolic, nutritional and mechanical complications, as well as psychological repercussions, complicate the therapeutic management of the patient and can lead to poor compliance, a deterioration in the general condition or even prolongation of hospitalizations and a delay in the implementation of chemotherapy cures. The control of induced chemo- and radio-induced nausea and vomiting rests above all on their prevention. At present and in most centers, the prevention of nausea and vomiting in the pediatric onco-hematology department of the CHU de Nice is based exclusively on drug treatments, according to a protocol established according to the emetogenic risk of the chemotherapy received. We propose a study evaluating the effectiveness of the stimulation of acupuncture points by low frequency laser therapy associated with antiemetics in the management of chemotherapy induced nausea and vomiting in patients of 2 to 20 years followed in the service of analgesics. pediatric onco-hematology.

Interventions

OTHERlaser therapy

stimulation of the acupuncture point P6 by laser therapy

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of malignant pathology with indication of chemotherapy with moderate to severe emetogenic potential * Indication of at least three identical chemotherapy cures * Age between 2 and 20 years * Prescription of an anti emetic protocol * Karnosky / Lansky Index\> 60%

Exclusion criteria

* Proven laser contraindication * Vomiting in the 24 hours before starting treatment * Presenting a brain lesion responsible for nausea and vomiting * Pelvic abdominal irradiation the week before the start of treatment * Treatment with benzodiazepines or opioids the week before treatment * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
The complete response to the preventive treatment of nausea and vomitingHours 72 after the end of chemotherapyThe complete response to the preventive treatment of nausea and vomiting defined by the absence of vomiting (active rejection by the mouth of part of the contents of the stomach), absence of nausea (effort of vomiting without active rejection) and the lack of emergency antiemetic treatment during the acute and delayed phase of chemotherapy (from the onset of chemotherapy to H72 after the end of chemotherapy).

Countries

France

Contacts

PRINCIPAL_INVESTIGATORMarilyne POIREE, MD

Centre Hospitalier Universitaire de Nice

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026